MGMT and glioma: QX302 exhibits significantly greater potency (approximately 2.37-fold) in MGMT-/MMR- glioma U87 cells compared to MGMT-/MMR+ glioma U251 cells, suggesting that MMR deficiency may play a role in conferring moderate resistance to QX302.